Aspirion vs Claimable
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Aspirion | Claimable | |
|---|---|---|
| Pricing model | Contingency (pay from recoveries) · Success-based, paid from recovered revenue | Per-transaction / per-chart · about $40-50 per appeal, some free |
| Speed to go live | Data feeds set up, they work inventory | consumer self-serve, appeal drafted in minutes |
| Automation model | Tech-enabled service · Attorneys and AI recover complex claims | AI copilot · drafts evidence-backed appeal letters |
| Built for | Enterprise systems | Small practices, Enterprise systems |
| Security posture | HITRUST, HIPAA | SOC 2 Type II, HIPAA |
| Company maturity | 14 yrs (est. 2012) | 3 yrs (est. 2023) |
| Financial backing | PE-owned (Linden Capital Partners) | $10M · Seed |
| Named customers | None public | None public |
| Published results | No public numbers | Specific numbers public |
| Documented integrations | None documented | None documented |
| Third-party validation | KLAS / analyst cited | None found |
Bottom line
- Pick Aspirion if you're a hospital with denials, MVA, workers' comp, or VA claims you can't work in-house and you'd rather pay only from what gets recovered.
- Pick Claimable if patients or one-off denials need fast, cheap, evidence-backed appeals with zero procurement.
Aspirion
Complex claims and denials recovery for hospitals
- Founded
- 2012
- HQ
- Columbus, GA
- Stage
- PE-owned (Linden Capital Partners)
- Raised
- n/a
What it does
- Clinical and technical denials appeals with attorney support
- Motor vehicle accident and workers' compensation claims
- VA, TRICARE, and out-of-state Medicaid billing
- Underpayment and zero-balance review
- Aged AR resolution
- AI-assisted appeal generation and claim prioritization
Where it's strong
- Named 2025 Best in KLAS for denials management, its second consecutive year, which is rare third-party validation in this segment.
- In-house attorneys and clinicians handle payer disputes most internal RCM teams cannot staff, and it serves over 140 clients including many of the largest US health systems.
- Contingency-style pricing ties fees to actual recoveries, keeping downside risk low for the provider.
What buyers should weigh
- It is a recovery service that works claims after the fact; it will not fix the upstream registration or coding problems causing the denials.
- The company has absorbed several acquisitions (Boost Healthcare, FIRM, Continuum), so ask which team and toolset will actually work your inventory.
- Contingency fees on high-dollar complex claims add up; model the effective rate against building internal capacity.
Claimable
AI-generated appeals for denied health insurance claims
- Founded
- 2023
- HQ
- Sacramento, CA
- Stage
- Seed
- Raised
- $10M
What it does
- AI-drafted appeals citing policy terms and medical literature
- Delivery to insurer appeals departments and executives
- Coverage for 28 conditions and 90+ treatments
- Support for 80+ medications including Humira and Dupixent
- Case tracking with most resolved within 10 days
Where it's strong
- Reports roughly 75 to 80% of appeals ending in overturned denials, far above typical patient appeal rates.
- Flat per-case pricing around $50 makes it accessible without a contract or implementation.
- Founding team combines clinical, payer, and VA data science backgrounds, and the escalation tactic of copying executives and regulators gets responses.
What buyers should weigh
- Coverage is limited to a defined list of conditions and treatments, so many denial types are out of scope today.
- The core product is patient-facing; provider and enterprise offerings are newer and less proven at volume.
- It appeals one claim at a time and does not address the upstream documentation or authorization issues driving denials.
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.